Hair cortisol may act as molecular biomarker for retinitis pigmentosa patients

Article

Patients with retinitis pigmentosa experience greater levels of stress and anxiety than individuals in the general population and that the level of stress can be measured easily and non-invasively in hair.

Hair cortisol may act as molecular biomarker for retinitis pigmentosa patients

Dr Milagros Mateos and colleagues from the Department of Ophthalmology of Clinical University Hospital of Valladolid and the Institute of Applied Ophthalmobiology, University of Valladolid, Valladolid, Spain, reported that the concentration of cortisol in hair may be an effective biomarker associated with chronic stress in patients with retinitis pigmentosa.

The authors explained that patients with RP experience greater levels of stress and anxiety than individuals in the general population and that the level of stress can be measured easily and non-invasively in hair. The stress is associated with the progressive and unpredictable and variable vision loss associated with the disease.

Study of hair samples

Dr Mateos and associates conducted a study in which they included 87 patients who were recruited from the Association of RP Patients from Casilla y Leon, Spain, between January 2019 and June 2021. The study also included 148 healthy controls.

All participants underwent an ophthalmologic examination that included clinical, structural, and functional tests, the results of which would be used divide patients by disease severity. An enzyme-linked immunosorbent assay was used to analyze the hair strands, and a questionnaire was administered to measure stress and anxiety levels.

Analysis results of RP by disease severity

The investigators reported that two-thirds of patients with RP had severe disease and the remaining third a mild-moderate stage of disease.

The questionnaire results indicated that 58 (58.9%) patients reported severe stress and anxiety and 18 (23.1%) highly elevated levels.

The patients with retinitis pigmentosa had higher level of cortisol in the hair samples (2.62 ± 0.14 Log10 pg/mg) compared with the controls (1.99 ± 0.23 Log10 pg/mg; P < 0.001). The patients with severe disease had significantly higher levels of cortisol in their hair than patients with mild-moderate RP, 2.71 ± 0.12 Log10 pg/mg and 2.43 ± 1.17 Log10 pg/mg (P < 0.011), respectively.

In addition, the severely anxious patients obtained a log-hair cortisol concentration that was higher than the patients experiencing less stress, 2.70 ± 0.24 Log10 pg/mg vs. 2.49 ± 0.19 Log10 pg/mg, although, the research team reported, the RP severity grade and perceived anxiety levels in the questionaries were not associated.

Dr Mateos and colleagues concluded, “The hair cortisol concentration seems to be an effective biomarker associated with chronic stress in patients with RP. This study shows that the hair cortisol concentrations in patients with RP are elevated compared to population-based controls, and an association between the concentration level and RP severity was identified. Future research is needed to characterize the effect of this untreated negative psychological states on progression of the disease if any.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.